他克莫司

tā kè mò sī
  • Tacrolimus
他克莫司他克莫司
  1. 他克莫司与环孢霉素治疗单纯性V型狼疮性肾炎的疗效比较

    Comparative Study on the Therapeutic Effect between Tacrolimus and Cyclosporine in the Treatment of Pure Class V Lupus Nephritis

  2. 他克莫司与环孢素A比较治疗胰肾联合移植术后排斥反应的Meta分析

    Tacrolimus versus Cyclosporine A for Simultaneous Pancreas-Kidney Transplant Recipients : A Meta-Analysis

  3. ELISA法监测肾移植患者他克莫司全血浓度448例次

    Monitoring of tacrolimus in 448 samples from renal transplant recipients by ELISA

  4. 他克莫司对转化生长因子-β诱导的肾小管上皮细胞转分化的抑制作用及对核因子-κB活性的影响

    Effects of FK506 on transdifferentiation and NF - κ B activity of human tubular cells induced by TGF - β in vitro

  5. 他克莫司用于中国肾移植患者远期疗效的Meta分析

    Long-term curative effect of tacrolimus in kidney transplantation patients in China : Meta-analysis

  6. 基于SVR的他克莫司血药浓度的预测模型

    Tacrolimus Blood Concentration Forecast Model based on Support Vector Regression

  7. 他克莫司及5-Fu对肝癌细胞株增殖及其血管内皮细胞生长因子表达的影响

    Effect of Tacrolimus Associated with 5-Fu on the Proliferation and the Expression of VEGF in Hepatocellular Carcinoma

  8. 他克莫司对炎症反应血清TNF-α、IL-1β含量的影响

    Effect of Tacrolimus on Serum TNF - α and IL-1 β Levels during Inflammatory Reactions Induced in Mice and Rats

  9. 小剂量他克莫司预处理有效减轻I八损伤引起的SOD、MDA、LDH改变。

    Low-dose FK506 preconditioning significantly reduced changes of SOD , MDA , LDH activities in intestinal mucosa associated with I / R injury .

  10. 环孢素+霉酚酸酯+强的松治疗组MS发病率高于他克莫司+霉酚酸酯+强的松治疗组,但差异无显著意义。

    There was no difference between the incidence of MS in recipients treated with cyclosporine + MMF + prednisone and recipients treated with tacrolimus + MMF + prednisone .

  11. 目的:比较0.1%,0.03%他克莫司软膏与赋形剂治疗中、重度特应性皮炎(AD)的疗效和安全性。

    Objective : To observe the clinical efficacy and safety of 0.1 % and 0.03 % tacrolimus cream in topical treatment of moderate to severe atopic dermatitis in adults .

  12. 结论他克莫司对体外培养的大鼠胰岛细胞有直接的损害作用,而Bcl-2能防治这种损害作用。

    Conclusion Tacrolimus may directly damage to isolated rat islet cells and the expression of Bcl-2 can protect the cells from the damage of immunosuppressive drugs .

  13. 他克莫司(Tacrolimus)是一种广泛使用的免疫抑制剂,可局部使用抑制角膜移植术后的排斥反应。

    Tacrolimus is one kind of widely used immunosuppressive agents , topical anti-rejection of corneal transplantation .

  14. 他克莫司(Tacrolimus,FK506)是一种强效的免疫抑制剂,因在水中溶解度低限制了其应用。

    Tacrolimus ( FK506 ) is a potent immunosuppressant , but its poor solubility restricted its application .

  15. 方法将36例斑块状银屑病患者随机分治疗组和对照组各18例,治疗组采用0.1%他克莫司软膏和尿素软膏外涂,bid,共治疗4周;

    Methods Thirty-six patients were randomized equally into 2 groups . The treatment group was treated topically with 0.1 % tacrolimus ointment plus 10 % urea ointment , bid .

  16. 联合应用NB-UVB与他克莫司对小鼠他克莫司透皮吸收及IL-10表达的影响

    Effects of NB-UVB Combined with Tacrolimus on Percutaneous Penetration of Tacrolimus and Expression of IL-10 in Mice

  17. 目的:评价他克莫司(FK506)用于肾移植患者免疫抑制治疗的效果与安全性。

    OBJECTIVE : To objectively evaluate the immunosuppressive effect and safety of tacrolimus ( FK506 ) in renal transplant recipients .

  18. 目的比较高危肾移植患者术后应用环孢素A(CsA)和他克莫司(FK506)的疗效和安全性。

    Objective To compare the efficiency and safety of CsA and FK506 used in the renal transplantation recipients with high risk factors .

  19. 新型免疫抑制剂效果强,副作用小,已倍受重视,例如他克莫司(FK506)、雷帕霉素(rapamycin,RAP)都是研发的热点。

    The neotype immunity inhibitors had the better effect of treatment , and little side effect , such as FK506 , rapamycin .

  20. 6例患者停用免疫抑制治疗,3例患者将他克莫司(FK506)或CsA降低到最低有效血药浓度。

    Patients were deprived of immunosuppression treatment and 3 patients received tacrolimus and cyclosporine with their blood levels kept in the low therapeutic range .

  21. 他克莫司对UVA照射后HaCaT细胞增殖的影响

    The Inhibitory Effect of Tacrolimus on the Proliferation of Keratinocytes Irradiated by UVA

  22. 目的探讨低血药浓度FK506(他克莫司)在肝移植方面的效果以及并发症的处理。

    Objective To discuss the immunosuppressive treatment of low blood concentration in FK506 in the aspects of liver transplanting and treatment of complications .

  23. 目的分析肝移植后需用环孢素A(CsA)替换他克莫司(FK506)的原因和结果。

    Objective To analyze the causes and outcome of conversion from tacrolimus ( FK506 ) to cyclosporine-A ( CsA ) in recipients after liver transplantation .

  24. 目的比较他克莫司(FK506)与环孢素A(CsA)预防肾移植术后排斥反应的效果和安全性。

    Objective To compare the effect and safety of taerolimus ( FK506 ) and cyclosporin ( CsA ) in the prevention of renal transplant rejection .

  25. 目的研究他克莫司(FK506)和来氟米特(Lef)对异种胰岛移植后急性排斥反应的抑制作用。

    Objective To assess the preventive effects of FK506 and Leflunomide ( Lef ) on islet xenograft acute rejection in rat-to-mouse models .

  26. 结果低剂量和高剂量的他克莫司都能诱导胰岛细胞凋亡,减少胰岛素分泌,Bcl-2能抑制凋亡,改善胰岛素分泌。

    Results Low and high concentrations of tacrolimus induced the apoptosis of islet cells and decreased insulin secretion . The Bcl-2 inhibited the apoptosis of islet cells induced by tacrolimus and improved the insulin secretion .

  27. Caco-2细胞转运实验证明了五酯胶囊可通过抑制P-gp对他克莫司的外排作用而使他克莫司口服生物利用度增加。

    The transport of tacrolimus using Caco-2 cell monolayers demonstrated that its bioavailability was enhanced when Wuzhi capsule inhibited the P-gp efflux pump . 5 .

  28. HPLC-MS/MS法与MEIA法在监测器官移植患者他克莫司全血浓度中的比较

    Comparison on two methods of HPLC-MS / MS and MEIA in monitoring the tacrolimus concentrations for organ transplantation patients

  29. 目的:探讨他克莫司(FK506)预处理对炎症反应血清肿瘤坏死因子(TNFα)、白细胞介素1β(IL1β)含量的影响。

    Objective : To study the effect of tarcrolimus ( FK506 ) on serum TNF - α and IL-1 β levels during inflammatory reactions induced in mice and rats .

  30. 目的观察他克莫司(FK506)对肠黏膜屏障的损伤以及谷氨酰胺(Gln)对该损伤的保护作用,并探讨其作用机制。

    OBJECTIVE To investigate the damage of tacrolimus ( FK506 ) to small intestinal mucosa barrier and the protective effect of glutamine ( Gln ) for the damage .